SEARCH:   Advanced

Blood, 28 May 2009, Vol. 113, No. 22, pp. 5617-5623. Prepublished online as a Blood First Edition Paper on March 9, 2009; DOI 10.1182/blood-2008-12-196014. This Article Full Text (PDF) All Versions of this Article: blood-2008-12-196014v1 113/22/5617    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dentali, F. Articles by Ageno, W. Search for Related Content PubMed PubMed Citation Articles by Dentali, F. Articles by Ageno, W. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted December 22, 2008 Accepted February 25, 2009 JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis Francesco Dentali*, Alessandro Squizzato, Lorenza Brivio, Lorena Appio, Leonardo Campiotti, Mark Crowther, Anna Maria Grandi, and Walter Ageno Department of Clinical Medicine, University of Insubria, Varese, Italy Department of Medicine, McMaster University, Hamilton, ON, Canada * Corresponding author; email: fdentali{at}libero.it. Recent studies suggested that JAK2V617F mutation is frequent in patients with splanchnic vein thrombosis (SVT) but not in patients with other venous thromboembolic events (VTE). However, whether screening for the JAK2V617F mutation in VTE patients is justified remains unclear. Therefore, we performed a systematic review to assess the frequency of JAK2 mutation in VTE patients and the role of JAK2V617F mutation in the diagnosis of myeloproliferative neoplasms (MPN). MEDLINE, EMBASE databases were searched. Two reviewers, independently, performed study selection, and extracted study characteristics. Pooled odds ratios (ORs) of case-control studies and weighted mean proportion of the prevalence of JAK2V617F mutation of uncontrolled series were calculated. 24 studies involving 3123 patients were included. Mean prevalence of JAK2 mutation was 32.7% (95%CI 25.5, 35.9%) in SVT patients. JAK2 mutation was associated with increased risk of SVT (OR, 53.98; 95% CI, 13.10, 222.45). Mean prevalence of JAK2 mutation in other VTE patients was low (range 0.88%, 2.57%). Presence of JAK2V617F mutation in SVT patients was associated with a subsequent diagnosis of MPN in many patients. JAK2 mutation is strongly associated with SVT and routine screening of JAK2 mutation appears to be indicated in these patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: JAK2 and Venous Thrombosis Journal Watch Oncology and Hematology, July 7, 2009; 2009(707): 1 - 1. [Full Text]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020